In the context of PC, preclinical and clinical studies demonstrated an altered myelopoiesis, driven by the release of pro-inflammatory cytokines and tumorigenic factors (IL-6, CCL-2, IL-10, GM-CSF, G-CSF, SCF and CCL2) that promote the mobilization of MDSCs from BM to TIME and a subsequent differentiation towards an immunosuppressive phenotype [43]. Here, CCL2 is linked to pachyonychia congenita.